Literature DB >> 17724067

Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.

Ahmad H Hussein1, Elisabeth M Davis, Scott A Halperin, Song F Lee.   

Abstract

A single-chain variable fragment (scFv) antibody library against Bordetella pertussis was constructed using M13 phage display. The library was enriched for phages surface displaying functional scFv by biopanning against B. pertussis immobilized on polystyrene plates. Two hundred eighty-eight individual clones from the enriched library were screened for binding to B. pertussis cells, filamentous hemagglutinin (FHA), and pertactin (PRN) in enzyme-linked immunosorbent assays (ELISAs). Based on the binding ability, the clones were put into eight groups. The scFv DNA inserts from the 288 clones were digested with BstOI, and 18 unique restriction patterns, named types 1 to 18, were found. Eight clones (types 1 to 7 and 18) were selected for further testing against FHA, PRN, and B. pertussis by ELISA. The results showed that types 1, 5, 7, and 18 bound strongly to B. pertussis cells as well as FHA and PRN. Type 3 bound strongly to the cells and FHA but weakly to PRN. Types 4 and 6 bound FHA only, and type 2 did not bind to the cells or antigens. The ability of the eight clones to inhibit B. pertussis from binding to HEp-2 cells was assayed. Types 1, 5, and 7, but not the remaining clones, inhibited the adherence of B. pertussis to HEp-2 cells. The scFvs were sequenced, and the deduced amino acid sequence showed that the scFvs were different antibodies. Maltose-binding protein (MBP) fusion proteins composed of three different regions of FHA (heparin-binding domain, carbohydrate recognition domain, and the RGD triplet motif) were constructed. The three fusion proteins and Mal85 (MBP-FHA type I domain) were used to map the binding sites for scFvs of types 1, 5, and 7 by ELISA. The results showed that all three scFvs bound to the heparin-binding domain fusion protein but not the other fusion proteins. BALB/c mice who received recombinant phage-treated B. pertussis had reduced bacterial counts in the nasal cavity, trachea, and lungs compared to the control groups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724067      PMCID: PMC2168280          DOI: 10.1128/IAI.00494-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

Review 1.  Immunity to Bordetella pertussis.

Authors:  K H Mills
Journal:  Microbes Infect       Date:  2001-07       Impact factor: 2.700

2.  Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in mice.

Authors:  Song F Lee; S A Halperin; H Wang; A MacArthur
Journal:  FEMS Microbiol Lett       Date:  2002-03-05       Impact factor: 2.742

3.  Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii.

Authors:  S F Lee; R J March; S A Halperin; G Faulkner; L Gao
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

4.  Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii.

Authors:  Song F Lee; Scott A Halperin; Jennifer B Knight; Aaron Tait
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

5.  Expression and immunogenicity of a recombinant diphtheria toxin fragment A in Streptococcus gordonii.

Authors:  Chiang W Lee; Song F Lee; Scott A Halperin
Journal:  Appl Environ Microbiol       Date:  2004-08       Impact factor: 4.792

6.  Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.

Authors:  Sylvie Alonso; Nathalie Reveneau; Kévin Pethe; Camille Locht
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

7.  In situ delivery of passive immunity by lactobacilli producing single-chain antibodies.

Authors:  Carina Krüger; Yanzhong Hu; Qiang Pan; Harold Marcotte; Anna Hultberg; Dipu Delwar; Philip J van Dalen; Peter H Pouwels; Rob J Leer; Charles G Kelly; Craig van Dollenweerd; Julian K Ma; Lennart Hammarström
Journal:  Nat Biotechnol       Date:  2002-07       Impact factor: 54.908

Review 8.  Oral colonization and immune responses to Streptococcus gordonii: Potential use as a vector to induce antibodies against respiratory pathogens.

Authors:  Song F Lee
Journal:  Curr Opin Infect Dis       Date:  2003-06       Impact factor: 4.915

9.  Role of adhesin release for mucosal colonization by a bacterial pathogen.

Authors:  Loic Coutte; Sylvie Alonso; Nathalie Reveneau; Eve Willery; Brigitte Quatannens; Camille Locht; Francoise Jacob-Dubuisson
Journal:  J Exp Med       Date:  2003-03-10       Impact factor: 14.307

10.  Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein.

Authors:  Song F Lee; Scott A Halperin; Danny F Salloum; Ann MacMillan; Annette Morris
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

View more
  3 in total

Review 1.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

Review 2.  Phage display derived peptides for Alzheimer's disease therapy and diagnosis.

Authors:  Xiancheng Zhang; Xiaoyu Zhang; Huiling Gao; Guangyan Qing
Journal:  Theranostics       Date:  2022-01-31       Impact factor: 11.556

Review 3.  Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.

Authors:  Philipp Kuhn; Viola Fühner; Tobias Unkauf; Gustavo Marcal Schmidt Garcia Moreira; André Frenzel; Sebastian Miethe; Michael Hust
Journal:  Proteomics Clin Appl       Date:  2016-06-21       Impact factor: 3.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.